Dendreon Corp fka DNDNQ

[rancherho]

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
http://biz.yahoo.com/prnews/080215/aqf043.html?.v=32
This is strong scientific validation for GVAX Phase 2 results. CEGE has also stated that they are archiving blood samples from all its Vital 1 and Vital 2 experimental arms (totalling 600 patients) for ongoing immunological testing. The results reported today suggests that immunological diagnostics from those samples might be a true biomarker during the therapy itself as to whether or not it is working wrt individual patients. This is potentially wonderful news for all cancer patients where the GVAX technology is being used.